Esperite

Esperite AAQS

Delisted

The The AAQS of Esperite (ESP.AS) as of Nov 19, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

Esperite has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Esperite in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Esperite AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2014
2.00 EUR
Jan 1, 2015
2.00 EUR
Jan 1, 2016
2.00 EUR
Jan 1, 2017
2.00 EUR
The Esperite AAQS history
YEARAAQSYoY
20.00%
20.00%
20.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Esperite Stock analysis

What does Esperite do? Esperite NV is a company based in the Netherlands that specializes in the development, production, and marketing of stem cell and cell therapies. It focuses on creating groundbreaking therapies for the treatment of serious diseases and aims to market them worldwide. Its business model includes three main segments: Life Science, Consumer Healthcare, and Branding. The Life Science segment focuses on developing stem cell and cell therapies for the treatment of diseases such as autism, cancer, and degenerative disorders. The Consumer Healthcare segment offers products related to pregnancy and fertility assistance. The Branding segment involves the development and marketing of high-quality cosmetic products. Esperite's flagship product is CryoSave, a solution for the long-term preservation of stem cells from umbilical cord blood. Esperite is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Esperite stock

The AAQS of Esperite is 2 in 2017.

On Eulerpool you can find the complete historical development of The AAQS Esperite since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Esperite

All Key Metrics — Esperite